

# Phathom<sup>®</sup>

## PHARMACEUTICALS

### Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

August 29, 2024

FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:

- **Morgan Stanley 22nd Annual Global Healthcare Conference** in New York, NY. Management will participate in one-on-one meetings throughout the conference, which runs from Wednesday, September 4 to Friday, September 6, 2024.
- **H.C. Wainwright 26th Annual Global Investment Conference** in New York, NY. Management will participate in a fireside chat on Monday, September 9, 2024, at 12:00 pm ET and one-on-one meetings throughout the day.

To access the live webcast and archived recording of the fireside chat, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. A recording will be available for 90 days following the conclusion of the event.

#### About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA<sup>®</sup> (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA<sup>®</sup> TRIPLE PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA<sup>®</sup> DUAL PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules) for the treatment of *H. pylori* infection in adults. For more information about Phathom, visit the company's website at [www.phathompharma.com](http://www.phathompharma.com) and follow on [LinkedIn](#) and [X](#).

#### MEDIA CONTACT

Nick Benedetto  
1-877-742-8466  
[media@phathompharma.com](mailto:media@phathompharma.com)

#### INVESTOR CONTACT

Eric Sciorilli  
1-877-742-8466  
[ir@phathompharma.com](mailto:ir@phathompharma.com)

© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.